{
  "nctId": "NCT03338374",
  "briefTitle": "Cardiac Resynchronisation Therapy Versus Rate-responsive Pacing in Heart Failure With Preserved Ejection Fraction",
  "officialTitle": "Heart Failure With Preserved Ejection Fraction Treated by Cardiac Resynchronisation Therapy Versus Rate Responsive Pacing: A Mechanistic Study",
  "protocolDocument": {
    "nctId": "NCT03338374",
    "filename": "Prot_SAP_001.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2017-09-14",
    "uploadDate": "2017-11-07T05:41",
    "size": 292233,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03338374/document/Prot_SAP_001.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 10,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-11-27",
    "completionDate": "2022-05-30",
    "primaryCompletionDate": "2022-05-30",
    "firstSubmitDate": "2017-08-31",
    "firstPostDate": "2017-11-09"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Confirmed HFpEF as described above\n* Chronotropic incompetence as described above\n* Ongoing exertional breathlessness of NYHA Grade II or worse\n* Ability to understand and sign written consent form\n* Males and females, age \\>18 years\n* Ability to participate in follow-up appointments at 3 and 6 months post-implantation\n* Ability to complete a cardiopulmonary exercise test\n\nExclusion Criteria:\n\n* Any contraindication to implantation of permanent pacemaker, namely unresolved infective process or sepsis, vascular access difficulties, advanced neoplastic process, expected lifespan less than 1 year or patient choice\n* Ejection fraction \\<50%\n* Known valvular disease graded severe or moderate-to-severe\n* Cardiac arrhythmia (paroxysmal or persistent) within 1 year of recruitment\n* Exertional chest pain suggestive of angina or personal history of coronary artery disease without subsequent revascularisation, or coronary angiogram within the past 5 years demonstrating \\>50% stenosis in â‰¥ 1 epicardial coronary artery\n* Significant chronic lung disease (FEV1 \\<80%)\n* Inability to complete follow-up process for any reason not defined above",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Diastolic reserve index",
        "description": "The change in e' between rest and exercise, as measured by tissue Doppler in the septal and/or lateral left ventricular walls on echocardiography. To be expressed using the formula: \\[change in e'\\] x \\[1-(1/e' at rest)\\]. e' is the peak diastolic velocity of the myocardium during passive left ventricular filling.",
        "timeFrame": "After 12 weeks of rate responsive pacing and again after 12 weeks of biventricular pacing; study extension: after 6 weeks of optimised pacing"
      },
      {
        "measure": "Systolic reserve index",
        "description": "The change in s' between rest and exercise, as measured by tissue Doppler in the septal and/or lateral left ventricular walls on echocardiography. To be expressed using the formula: \\[change in s'\\] x \\[1-(1/s' at rest)\\]. s' is the peak systolic velocity of the myocardium.",
        "timeFrame": "After 12 weeks of rate responsive pacing and again after 12 weeks of biventricular pacing; study extension: after 6 weeks of optimised pacing"
      }
    ],
    "secondary": [
      {
        "measure": "Global longitudinal strain",
        "description": "Peak systolic strain of 6 myocardial segments measured on echocardiography by speckle tracking, measured both at rest and on exercise",
        "timeFrame": "After 12 weeks of rate responsive pacing and again after 12 weeks of biventricular pacing; study extension: after 6 weeks of optimised pacing"
      },
      {
        "measure": "Left ventricular torsion",
        "description": "The twisting movement of the heart can be quantified with echocardiography using speckle tracking at rest and on exercise.",
        "timeFrame": "After 12 weeks of rate responsive pacing and again after 12 weeks of biventricular pacing; study extension: after 6 weeks of optimised pacing"
      },
      {
        "measure": "Exercise duration",
        "description": "Cardiopulmonary exercise testing will be used with standard local protocols to evaluate exercise duration.",
        "timeFrame": "After 12 weeks of rate responsive pacing and again after 12 weeks of biventricular pacing; study extension: after 6 weeks of optimised pacing"
      },
      {
        "measure": "Oxygen carrying capacity",
        "description": "Measurement of peak ventilatory capacity (VO2 max) using cardiopulmonary exercise testing with standard local protocols, ensuring a respiratory exchange ratio of greater than 1.1 to guarantee near-maximal exercise achieved. This will be assessed using expired gas analysis, which is a standard technique.",
        "timeFrame": "After 12 weeks of rate responsive pacing and again after 12 weeks of biventricular pacing; study extension: after 6 weeks of optimised pacing"
      },
      {
        "measure": "Distance walked in a six-minute walk test",
        "description": "Subjects walk down a pre-measured course, usually a hallway or corridor, and their distance achieved after six minutes is recorded.",
        "timeFrame": "After 12 weeks of rate responsive pacing and again after 12 weeks of biventricular pacing; study extension: after 6 weeks of optimised pacing"
      },
      {
        "measure": "New York Heart Association Function Class",
        "description": "Standard measure of heart failure severity that correlates with outcomes. Assessed using measures of impairment in activities of daily living, such as dressing, walking.",
        "timeFrame": "After 12 weeks of rate responsive pacing and again after 12 weeks of biventricular pacing; study extension: after 6 weeks of optimised pacing"
      },
      {
        "measure": "Minnesota Living with Heart Failure Quality of Life Score",
        "description": "Change in Minnesota living with heart failure questionnaire score. This questionnaire asks 21 questions relating to daily tasks of living, hobbies, social life and well-being in relation to heart failure symptoms and ascribes greater points to more severe symptoms; a higher score is therefore indicative of a lower quality of life. Scores may range between 0 and 105.",
        "timeFrame": "After 12 weeks of rate responsive pacing and again after 12 weeks of biventricular pacing; study extension: after 6 weeks of optimised pacing"
      },
      {
        "measure": "Prognostic biomarkers",
        "description": "Measurement of serum N-terminal pro-B-type Natriuretic Peptide, a commonly used marker of ventricular wall stretch that correlates with heart failure severity and is adversely associated with prognosis.",
        "timeFrame": "After 12 weeks of rate responsive pacing and again after 12 weeks of biventricular pacing; study extension: after 6 weeks of optimised pacing"
      }
    ],
    "other": [
      {
        "measure": "Drop-out rate",
        "description": "A measure of the number of participants who fail to complete the study processes, to inform further studies using a similar design",
        "timeFrame": "At 24 weeks (or if study extension used, then following completion of this 6-week extension)"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 8,
      "otherCount": 1,
      "totalCount": 11
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 66,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:29:31.211Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}